JNJ - Emergent awaiting FDA OK to release 60M J&J vaccine doses - Bloomberg

Emergent BioSolutions (EBS) has 60M doses of Johnson & Johnson's (JNJ) COVID-10 ready to distribute as soon as the FDA gives authorization to release it, Bloomberg reports.Vaccine production at the company's key Baltimore production facility has been stalled since mid-April as the FDA conducted an investigation of the plant after the company had to throw away 15M J&J COVID-19 vaccine doses due to a manufacturing mix-up in late March.The inspection subsequently found major deficiencies.Emergent reports Q1 earnings after the closing bell today.Emergent shares are up 1.8% to $63.19 and J&J shares are up 1.2% to $163.93 in afternoon trading.

For further details see:

Emergent awaiting FDA OK to release 60M J&J vaccine doses - Bloomberg